OBJECTIVE: Few studies have compared treatment outcomes of African-American, Hispanic, and non-Hispanic white patients with bipolar disorder. The U.S. Systematic Treatment Enhancement Program for Bipolar Disorder compared one-year outcomes for bipolar I or II disorder from each of these racial-ethnic groups. METHODS: African Americans (N=155) were retrospectively compared with a matched group of non-Hispanic whites (N=729), and Hispanics (N=152) were compared with a separate matched group of non-Hispanic whites (N=822). Response and recovery outcomes were examined. Survival analysis was used to compare time to treatment response for depression (Montgomery-Asberg Depression Rating Scale) and mania (Young Mania Rating Scale) as well as global assessment of functioning (Global Assessment of Functioning). RESULTS: For manic and depressive symptoms, time to response and proportion of responders were similar across groups. Over the study year the proportion of days well was similar across groups. A smaller proportion of African Americans met criteria for improved global functioning. Depression response among African Americans with psychotic symptoms was slower than the response among African Americans without psychotic symptoms and among non-Hispanic whites with or without psychotic symptoms. No differences between Hispanics and non-Hispanic whites in response times and recovery were observed. CONCLUSIONS: Results are consistent with U.S. clinical trials for other psychiatric disorders, which have reported similar outcomes for ratings of primary symptoms. Baseline psychotic symptoms are likely a significant contributor when African Americans with bipolar disorder are slow to recover. These results may be less generalizable to uninsured patients.
OBJECTIVE: Few studies have compared treatment outcomes of African-American, Hispanic, and non-Hispanic white patients with bipolar disorder. The U.S. Systematic Treatment Enhancement Program for Bipolar Disorder compared one-year outcomes for bipolar I or II disorder from each of these racial-ethnic groups. METHODS: African Americans (N=155) were retrospectively compared with a matched group of non-Hispanic whites (N=729), and Hispanics (N=152) were compared with a separate matched group of non-Hispanic whites (N=822). Response and recovery outcomes were examined. Survival analysis was used to compare time to treatment response for depression (Montgomery-Asberg Depression Rating Scale) and mania (Young Mania Rating Scale) as well as global assessment of functioning (Global Assessment of Functioning). RESULTS: For manic and depressive symptoms, time to response and proportion of responders were similar across groups. Over the study year the proportion of days well was similar across groups. A smaller proportion of African Americans met criteria for improved global functioning. Depression response among African Americans with psychotic symptoms was slower than the response among African Americans without psychotic symptoms and among non-Hispanic whites with or without psychotic symptoms. No differences between Hispanics and non-Hispanic whites in response times and recovery were observed. CONCLUSIONS: Results are consistent with U.S. clinical trials for other psychiatric disorders, which have reported similar outcomes for ratings of primary symptoms. Baseline psychotic symptoms are likely a significant contributor when African Americans with bipolar disorder are slow to recover. These results may be less generalizable to uninsured patients.
Authors: H W Neighbors; S J Trierweiler; C Munday; E E Thompson; J S Jackson; V J Binion; J Gomez Journal: J Natl Med Assoc Date: 1999-11 Impact factor: 1.798
Authors: David Garver; Arthur Lazarus; Kitty Rajagopalan; Lois Lamerato; Laura M Katz; Lee S Stern; Margarita Dolgitser; John J Doyle Journal: Psychiatr Serv Date: 2006-05 Impact factor: 3.084
Authors: Jodi M Gonzalez; Peter Thompson; Michael Escamilla; Mako Araga; Vivek Singh; Niamh Farrelly; Michael E Thase; David J Miklowitz; Charles L Bowden Journal: Psychopharmacol Bull Date: 2007
Authors: Kathleen R Merikangas; Hagop S Akiskal; Jules Angst; Paul E Greenberg; Robert M A Hirschfeld; Maria Petukhova; Ronald C Kessler Journal: Arch Gen Psychiatry Date: 2007-05
Authors: Ann Marie Yamada; Concepción Barrio; Susan W Morrison; Dan Sewell; Dilip V Jeste Journal: Gen Hosp Psychiatry Date: 2006 Mar-Apr Impact factor: 3.238
Authors: C L Bowden; V Singh; P Thompson; J M Gonzalez; M M Katz; M Dahl; T J Prihoda; X Chang Journal: Acta Psychiatr Scand Date: 2007-09 Impact factor: 6.392
Authors: Jorge M Tamayo; Guido Mazzotti; Mauricio Tohen; Wagner F Gattaz; Ricardo Zapata; José J Castillo; Rodolfo D Fahrer; Ana M González-Pinto; Eduard Vieta; Jean M Azorin; Eileen Brown; Elizabeth Brunner; Jorge Rovner; Elena Bonett-Perrin; Robert W Baker Journal: J Clin Psychopharmacol Date: 2007-04 Impact factor: 3.153
Authors: Jodi Gonzalez Arnold; Stephanie Salcedo; Terrence A Ketter; Joseph R Calabrese; Dustin J Rabideau; Andrew A Nierenberg; Melissa Bazan; Andrew C Leon; Edward S Friedman; Dan Iosifescu; Louisa G Sylvia; Michael Ostacher; Michael Thase; Noreen A Reilly-Harrington; Charles L Bowden Journal: J Affect Disord Date: 2015-03-14 Impact factor: 4.839
Authors: Margaret O Akinhanmi; Joanna M Biernacka; Stephen M Strakowski; Susan L McElroy; Joyce E Balls Berry; Kathleen R Merikangas; Shervin Assari; Melvin G McInnis; Thomas G Schulze; Marion LeBoyer; Carol Tamminga; Christi Patten; Mark A Frye Journal: Bipolar Disord Date: 2018-03-12 Impact factor: 6.744